These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 36768547)

  • 1. CD14
    Olivieri O; Gasperini S; Calzetti F; Gardiman E; Castagna A; Martinelli N; Tamassia N; Cassatella MA
    Int J Mol Sci; 2023 Jan; 24(3):. PubMed ID: 36768547
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Toll-like receptor 2 mediates apolipoprotein CIII-induced monocyte activation.
    Kawakami A; Osaka M; Aikawa M; Uematsu S; Akira S; Libby P; Shimokado K; Sacks FM; Yoshida M
    Circ Res; 2008 Dec; 103(12):1402-9. PubMed ID: 18974386
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Apolipoprotein CIII in apolipoprotein B lipoproteins enhances the adhesion of human monocytic cells to endothelial cells.
    Kawakami A; Aikawa M; Libby P; Alcaide P; Luscinskas FW; Sacks FM
    Circulation; 2006 Feb; 113(5):691-700. PubMed ID: 16461842
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Apolipoprotein CIII links dyslipidemia with atherosclerosis.
    Kawakami A; Yoshida M
    J Atheroscler Thromb; 2009 Mar; 16(1):6-11. PubMed ID: 19262004
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Associations of genotypes at the apolipoprotein AI-CIII-AIV, apolipoprotein B and lipoprotein lipase gene loci with coronary atherosclerosis and high density lipoprotein subclasses.
    Peacock RE; Hamsten A; Johansson J; Nilsson-Ehle P; Humphries SE
    Clin Genet; 1994 Oct; 46(4):273-82. PubMed ID: 7834891
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The effects of selective complement and CD14 inhibition on the E. coli-induced tissue factor mRNA upregulation, monocyte tissue factor expression, and tissue factor functional activity in human whole blood.
    Brekke OL; Waage C; Christiansen D; Fure H; Qu H; Lambris JD; Østerud B; Nielsen EW; Mollnes TE
    Adv Exp Med Biol; 2013; 735():123-36. PubMed ID: 23402023
    [TBL] [Abstract][Full Text] [Related]  

  • 7. ApoCIII as a Cardiovascular Risk Factor and Modulation by the Novel Lipid-Lowering Agent Volanesorsen.
    Rocha NA; East C; Zhang J; McCullough PA
    Curr Atheroscler Rep; 2017 Nov; 19(12):62. PubMed ID: 29124482
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Apolipoprotein CIII induces expression of vascular cell adhesion molecule-1 in vascular endothelial cells and increases adhesion of monocytic cells.
    Kawakami A; Aikawa M; Alcaide P; Luscinskas FW; Libby P; Sacks FM
    Circulation; 2006 Aug; 114(7):681-7. PubMed ID: 16894036
    [TBL] [Abstract][Full Text] [Related]  

  • 9. ABCA1 promotes the de novo biogenesis of apolipoprotein CIII-containing HDL particles in vivo and modulates the severity of apolipoprotein CIII-induced hypertriglyceridemia.
    Kypreos KE
    Biochemistry; 2008 Sep; 47(39):10491-502. PubMed ID: 18767813
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Metabolism of very-low-density lipoprotein and low-density lipoprotein containing apolipoprotein C-III and not other small apolipoproteins.
    Mendivil CO; Zheng C; Furtado J; Lel J; Sacks FM
    Arterioscler Thromb Vasc Biol; 2010 Feb; 30(2):239-45. PubMed ID: 19910636
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Statins suppress apolipoprotein CIII-induced vascular endothelial cell activation and monocyte adhesion.
    Zheng C; Azcutia V; Aikawa E; Figueiredo JL; Croce K; Sonoki H; Sacks FM; Luscinskas FW; Aikawa M
    Eur Heart J; 2013 Feb; 34(8):615-24. PubMed ID: 22927557
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Recent Apolipoprotein CIII trials.
    Tramontano D; Bini S; D'Erasmo L; Arca M
    Curr Opin Lipidol; 2022 Dec; 33(6):309-318. PubMed ID: 36206093
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Apolipoprotein CIII-induced THP-1 cell adhesion to endothelial cells involves pertussis toxin-sensitive G protein- and protein kinase C alpha-mediated nuclear factor-kappaB activation.
    Kawakami A; Aikawa M; Nitta N; Yoshida M; Libby P; Sacks FM
    Arterioscler Thromb Vasc Biol; 2007 Jan; 27(1):219-25. PubMed ID: 17038637
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Updates on apolipoprotein CIII: fulfilling promise as a therapeutic target for hypertriglyceridemia and cardiovascular disease.
    Zheng C
    Curr Opin Lipidol; 2014 Feb; 25(1):35-9. PubMed ID: 24345989
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Apolipoprotein CIII and diabetes. Is there a link?
    Christopoulou E; Tsimihodimos V; Filippatos T; Elisaf M
    Diabetes Metab Res Rev; 2019 Mar; 35(3):e3118. PubMed ID: 30557902
    [TBL] [Abstract][Full Text] [Related]  

  • 16. IL-33 stimulates the release of procoagulant microvesicles from human monocytes and differentially increases tissue factor in human monocyte subsets.
    Stojkovic S; Thulin Å; Hell L; Thaler B; Rauscher S; Baumgartner J; Gröger M; Ay C; Demyanets S; Neumayer C; Huk I; Spittler A; Huber K; Wojta J; Siegbahn A; Åberg M
    Thromb Haemost; 2017 Jun; 117(7):1379-1390. PubMed ID: 28492698
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Apolipoprotein CIII links hyperlipidemia with vascular endothelial cell dysfunction.
    Kawakami A; Osaka M; Tani M; Azuma H; Sacks FM; Shimokado K; Yoshida M
    Circulation; 2008 Aug; 118(7):731-42. PubMed ID: 18663085
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The Positive Association between Plasma Myristic Acid and ApoCIII Concentrations in Cardiovascular Disease Patients Is Supported by the Effects of Myristic Acid in HepG2 Cells.
    Olivieri O; Speziali G; Castagna A; Pattini P; Udali S; Pizzolo F; Liesinger L; Gindlhuber J; Tomin T; Schittmayer M; Birner-Gruenberger R; Cecconi D; Girelli D; Friso S; Martinelli N
    J Nutr; 2020 Oct; 150(10):2707-2715. PubMed ID: 32710763
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Apolipoprotein CIII predicts cardiovascular events in patients with coronary artery disease: a prospective observational study.
    Katzmann JL; Werner CM; Stojakovic T; März W; Scharnagl H; Laufs U
    Lipids Health Dis; 2020 May; 19(1):116. PubMed ID: 32473635
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Apolipoproteins E and CIII interact to regulate HDL metabolism and coronary heart disease risk.
    Morton AM; Koch M; Mendivil CO; Furtado JD; Tjønneland A; Overvad K; Wang L; Jensen MK; Sacks FM
    JCI Insight; 2018 Feb; 3(4):. PubMed ID: 29467335
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.